Arikayce is the first therapy approved in the US specifically for patients with MAC lung disease The Food and Drug Administration (FDA) has approved Arikayce (amikacin liposome inhalation suspension for oral inhalation; Insmed) for adults who have limited or no alternative treatment options, for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. Arikayce is the first drug approved under the. 'This pathway, advanced by Congress, aims to spur development of drugs targeting infections that lack effective therapies,' said FDA Commissioner Scott Gottlieb, MD. 'We're seeing a lot of early interest among sponsors in using this new pathway, and it's our hope that it'll spur more development and approval of antibacterial drugs for treating serious or life-threatening infections in limited populations of patients with unmet medical needs.' Related Articles. The approval was based on data from the Phase 3 CONVERT study in patients with refractory MAC lung disease (N=336) as confirmed by at least 2 sputum culture results.

• Unique Nebulizer And Drug Combo Approved For Macular Degeneration

Unique Nebulizer And Drug Combo Approved For Macular Degeneration

Patients were randomized to receive Arikayce plus a background multi-drug antibacterial regimen or background regimen alone. Results showed that the proportion of patients achieving culture conversion (3 consecutive monthly negative sputum cultures) by the sixth month of treatment was significantly ( P.

Conclusion: Why use Disk Drill Software? • It recovers all the photos from old history. • The First point is that It is free to use anywhere. Disk drill for mac review.